Literature DB >> 3667568

Fibrinogens Kawaguchi and Osaka: an amino acid substitution of A alpha arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two A alpha chains.

T Miyata1, S Terukina, M Matsuda, A Kasamatsu, Y Takeda, T Murakami, S Iwanaga.   

Abstract

Structural analyses of fibrinogens from patients with congenital dysfibrinogenemia, designated as fibrinogens Kawaguchi and Osaka, have been performed to identify the difference responsible for the lack of fibrinopeptide A release. For the structural studies, a new strategy was employed. Amino acid sequence analysis of one of the lysyl endopeptidase-peptides isolated from the abnormal fibrinogens indicated that in both fibrinogens, arginine-16 of the A alpha chain had been replaced by cysteine. To characterize the chemical nature of the sulfhydryl group of cysteine-16, a tryptic peptide containing cysteine-16 of the A alpha chain was prepared from intact fibrinogen Kawaguchi. The amino acid composition and the molecular weight determination of this aberrant peptide revealed that it was a dimeric NH2-terminal peptide corresponding to residues 1-19 derived from the abnormal A alpha chain. These results indicate that the half-cystine at position 16 in the abnormal A alpha chain forms an intramolecular disulfide bridge with the same residue in the other abnormal A alpha chain and that fibrinogen Kawaguchi is a homo dimer composed of two identical abnormal halves.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667568     DOI: 10.1093/oxfordjournals.jbchem.a122046

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

1.  Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly.

Authors:  D K Galanakis; A Henschen; E I Peerschke; M Kehl
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

2.  Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexes.

Authors:  J Koopman; F Haverkate; J Grimbergen; L Engesser; I Nováková; A F Kerst; S T Lord
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

3.  Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).

Authors:  A M Aly; M Arai; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer.

Authors:  Yidi Chen; Jiang Huang; Yuying Zhang; Jinhuan Xie; Yiqiong Liang; Wenzhao Yuan; Ting Zhou; Ruizhi Gao; Rong Wen; Yuwei Xia; Liling Long
Journal:  Abdom Radiol (NY)       Date:  2021-10-12

5.  Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution.

Authors:  K Yamazumi; S Terukina; M Matsuda; J Kanbayashi; M Sakon; T Tsujinaka
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

6.  Fib420: a normal human variant of fibrinogen with two extended alpha chains.

Authors:  Y Fu; G Grieninger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 7.  Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.

Authors:  Meiling Luo; Aiqiu Wei; Liqun Xiang; Jie Yan; Lin Liao; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.